A practical reference on salt form: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-05 and is reviewed periodically as new material appears.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
== Wear == The effect of wear on a roller chain is to increase the pitch (spacing of the links), causing the chain to grow longer. Note that this is due to wear at the pivoting pins and bushes, not from actual stretching of the metal (as does happen to some flexible steel components such as the hand-brake cable of a motor vehicle). With modern chains it is unusual for a chain (other than that of a bicycle) to wear until it breaks, since a worn chain leads to the rapid onset of wear on the teeth of the sprockets, with ultimate failure being the loss of all the teeth on the sprocket. The sprockets (in particular the smaller of the two) suffer a grinding motion that puts a characteristic hook shape into the driven face of the teeth. (This effect is made worse by a chain improperly tensioned, but is unavoidable no matter what care is taken). The worn teeth (and chain) no longer provides smooth transmission of power and this may become evident from the noise, the vibration or (in car engines using a timing chain) the variation in ignition timing seen with a timing light. Both sprockets and chain should be replaced in these cases, since a new chain on worn sprockets will not last long. However, in less severe cases it may be possible to save the larger of the two sprockets, since it is always the smaller one that suffers the most wear. Only in very light-weight applications such as a bicycle, or in extreme cases of improper tension, will the chain normally jump off the sprockets. The lengthening due to wear of a chain is calculated by the following formula:
=== Max Braverman === Max Braverman (Max Burkholder) is Adam and Kristina's son (age 8 in the series pilot episode, although he is 14 in season 5) who is diagnosed with Asperger's syndrome at the beginning of the first season. His struggles and triumphs with this syndrome affect much of what happens in his family. Max is unaware of his diagnosis in the early episodes (although he is enthusiastic about participating in a "Walk for Autism"), but during the second season he learns about it after witnessing an argument between Adam and Crosby. His parents decide to transfer him to a mainstream school after being told that Max is very intelligent. In the season 2 finale, while at the hospital Max becomes very angry, saying that he wants pancakes more than he cares about Amber, even going as far as saying that doesn't care about her. Adam scolds Max for his hurtful comments, but Max believes he didn't do anything wrong, though at the end he apologizes to Sarah for what he said. In season 3, Max has been mainstreamed into a normal school, to challenge him academically. He is trying hard to make friends, though it proves difficult. He does make a friend in season 3, a boy with spina bifida named Micah, whose parents are thrilled because, like Max, he's never had a friend before. It is also discovered that Max is academically gifted. Though socially behind others his age, he is academically far above most others his age and older. In the fourth season, he is elected class president of Cedar Knoll Middle School with some help from his older sister Haddie.
== Adoption and competitors == OC/RDC are used in academic and government networks, as well as in corporate environments. Other products in the same or adjacent space include Medidata Rave, REDCap, and Veeva Vault EDC.
Anthraquinone glycosides are found in senna, rhubarb, and Aloe. The cardiac glycosides are phytochemicals from plants including foxglove and lily of the valley. They include digoxin and digitoxin which act as diuretics.
=== Glycoprotein Ia / IIa complex (GPIa / IIa = integrin α2β1) === This is a receptor for collagen type I and IV. It consists of two subunits (α2 and β1). The α2 subunit includes a domain homologous to von Willebrand factor domain binding to collagen. The β1 subunit has four cysteine-rich regions and a structure similar to other β-integrins. The interaction with collagen leads to stabilization of the platelets. The surface expression of this complex shows high variability, particularly in relation to the polymorphism of GPIa subunit gene. Different opinions exist on the importance of C - T point mutation at position 807, which is believed to be associated with the risk of myocardial infarction or ischemic stroke.
Sources: en.wikipedia.org
=== Federal government initiative === A 2026 executive order directed US agencies to accelerate research, regulatory review, and potential patient access pathways for psychedelic drugs, including ibogaine, for serious mental illness.
=== Natural hypoallergenic milk for infants with cows' milk protein allergy === Pasteurized donkey milk is used as a natural hypoallergenic milk because it is tolerated by about 90% of infants with food allergies, e.g., cows' milk protein allergy (CMPA), a common food allergy in childhood with a prevalence of approximately 3% during the first 3 years of life. However, an infant's tolerance to donkey milk must be evaluated under medical supervision, and after carrying out specific allergy tests. Natural hypoallergenic formula is preferred over those of soy or produced from protein hydrolysates because it has a pleasant taste and may not cause allergies in people who also have allergic reactions to soy proteins or protein hydrolysates.
== Left-handed structure == In principle, a left-handed version of the π-helix is possible by reversing the sign of the (φ, ψ) dihedral angles to (55°, 70°). This pseudo-"mirror-image" helix has roughly the same number of residues per turn (4.1) and helical pitch (1.5 Å [150 pm]). It is not a true mirror image, because the amino-acid residues still have a left-handed chirality. A long left-handed π-helix is unlikely to be observed in proteins because, among the naturally occurring amino acids, only glycine is likely to adopt positive φ dihedral angles such as 55°.
Metalloids are sometimes called semimetals, a practice that has been discouraged, as the term semimetal has a more common usage as a specific kind of electronic band structure of a substance. In this context, only arsenic and antimony are semimetals, and commonly recognised as metalloids.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.